Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period ActivityBusiness Wire • 02/11/21
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial ResultsBusiness Wire • 01/28/21
Alnylam Launches “Alnylam P5x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five YearsBusiness Wire • 01/10/21
Alnylam Pharmaceuticals Logs Another Clinical Win For Its Amyloidosis ProgramSeeking Alpha • 01/08/21
Alnylam (ALNY) Posts Positive Top-Line Data From Vutrisiran StudyZacks Investment Research • 01/08/21
Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with PolyneuropathyBusiness Wire • 01/07/21
Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/04/21
Alnylam Appoints Tolga Tanguler Chief Commercial Officer and Also Announces New CEMEA, Medical Affairs, and Compliance LeadersBusiness Wire • 12/21/20
Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D DayBusiness Wire • 12/15/20
Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company's Approved TherapiesBusiness Wire • 12/07/20
Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1Business Wire • 12/03/20
Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO™ (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing Solutions to U.S. PayersBusiness Wire • 11/24/20
Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult PatientsBusiness Wire • 11/24/20
Alnylam Receives Approval for OXLUMO™ (lumasiran) in the European Union for the Treatment of Primary Hyperoxaluria Type 1 in All Age GroupsBusiness Wire • 11/19/20
Alnylam Seeing A Rebound In Onpattro And Encouraging Early-Stage Hypertension DataSeeking Alpha • 11/17/20
Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of HypertensionBusiness Wire • 11/13/20